Last reviewed · How we verify
Livzon Pharmaceutical Group Inc. — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
4 Phase 3
3 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Esoprazole | Esoprazole | marketed | Other | |||
| amoxicillin and clarithromycin | amoxicillin and clarithromycin | marketed | ||||
| Ilaprazole tablet | Ilaprazole tablet | phase 3 | Proton pump inhibitor (PPI) | H+/K+-ATPase (proton pump) | Gastroenterology | |
| JP-1366 simulation tablets | JP-1366 simulation tablets | phase 3 | ||||
| LZM012 | LZM012 | phase 3 | ||||
| SARS-Cov-2 Vaccine Inactivated | SARS-Cov-2 Vaccine Inactivated | phase 3 | Immunology |
Therapeutic area mix
- Other · 2
- Cardiovascular · 1
- Gastroenterology · 1
- Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Baxter · 1 shared drug class
- Ain Shams University · 1 shared drug class
- AstraZeneca · 1 shared drug class
- AstraZeneca (originally Astra AB) · 1 shared drug class
- Ace Cells Lab Limited · 1 shared drug class
- Abbott · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Livzon Pharmaceutical Group Inc.:
- Livzon Pharmaceutical Group Inc. pipeline updates — RSS
- Livzon Pharmaceutical Group Inc. pipeline updates — Atom
- Livzon Pharmaceutical Group Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Livzon Pharmaceutical Group Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/livzon-pharmaceutical-group-inc. Accessed 2026-05-17.